Surveillance of Advanced Adenoma with High‑Grade Dysplasia
Definition and Baseline Risk
- An adenoma that shows high‑grade dysplasia is classified as an advanced adenoma regardless of its size or histology (US Multi‑Society Task Force) 1.
- Advanced adenoma is defined as any adenoma with high‑grade dysplasia, tubulovillous/villous histology, or size ≥ 10 mm (US Multi‑Society Task Force) 1.
- In the absence of a family history of colorectal cancer, a 38‑year‑old patient is considered average‑risk, with an approximate 4 % lifetime risk of colorectal cancer (American College of Gastroenterology) 3.
Recommended Surveillance Interval
- The US Multi‑Society Task Force issues a strong recommendation (moderate‑quality evidence) for a repeat colonoscopy at 3 years after removal of any adenoma containing high‑grade dysplasia (US Multi‑Society Task Force) 1.
Procedural Quality Requirements for the 3‑Year Interval
- Surveillance colonoscopy should be performed with:
Situations Requiring Modified Surveillance
- If the adenoma was removed piecemeal and measured ≥ 20 mm, the next colonoscopy should be scheduled at 6 months rather than 3 years (US Multi‑Society Task Force) 1.
- When a patient accumulates more than 10 adenomas over time, a genetic evaluation should be considered (US Multi‑Society Task Force) 1; hereditary syndromes such as Lynch syndrome or polyposis would then require distinct management strategies (American College of Gastroenterology) 3.
Common Pitfalls to Avoid
- Do not extend the surveillance interval beyond 3 years solely because of the patient’s young age; high‑grade dysplasia mandates the standard 3‑year follow‑up (US Multi‑Society Task Force) 1.
- Do not substitute non‑invasive stool‑based tests (e.g., FIT, stool DNA) for colonoscopic surveillance in this setting; colonoscopy remains required (US Multi‑Society Task Force) 1.
- Do not assume that a single adenoma with high‑grade dysplasia is low risk; by definition it is an advanced neoplasm requiring the recommended surveillance (US Multi‑Society Task Force) 1.
- The above recommendations do not apply if a family history of colorectal cancer emerges or if a hereditary syndrome is diagnosed; management should then follow the appropriate hereditary‑cancer guidelines (US Multi‑Society Task Force) 1.